XML 75 R52.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Investments in Associates (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2018
Disclosure Of Significant Investments In Associates [Abstract] |
Summary of Changes in Investments in Associates Accounted for Using Equity Method | The following table outlines changes in the investments in associates that are accounted for using the equity method. In accordance with IAS 28 Investments in Associates and Joint Ventures in cases where the Company does not have the same reporting date as its associates the Company will account for its investment one quarter in arrears. Accordingly the figures in the following tables are based on values at December 31, 2017 with adjustments for any significant transactions.
|  |  |  |  |  | Participating |  |  | Balance at |  |  |  |  |  |  | Share of net |  |  |  |  |  |  | Balance at |
|  |  |  |  |  | share |  |  | March 31, |  |  |  |  |  |  | (loss)/ |  |  | Interest |  |  | March 31, |
Entity |  | Instrument |  | Note |  |  |  |  |  | 2017 |  |  | Additions |  |  | income |  |  | income |  |  | 2018 |
Agripharm |  | shares |  | 10(c) |  |  | 40.0 | % |  | $ | - |  |  | $ | 38,711 |  |  | $ | (232 | ) |  | $ | - |  |  | $ | 38,479 |
TerrAscend |  | shares |  | 15(i) |  |  | 24.0 | % |  |  | - |  |  |  | 16,978 |  |  |  | (66 | ) |  |  | - |  |  |  | 16,912 |
Radicle |  | convertible debenture |  | 15(ii) |  |  | 23.8 | % |  |  | - |  |  |  | 5,000 |  |  |  | (136 | ) |  |  | (110 | ) |  |  | 4,754 |
CHI |  | shares |  | 15(iii) |  |  | 43.0 | % |  |  | - |  |  |  | 4,000 |  |  |  | (1,039 | ) |  |  | - |  |  |  | 2,961 |
Bedrocan Brasil |  | shares |  | 15(iv) |  |  | 39.8 | % |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Entourage |  | shares |  | 15(iv) |  |  | 40.0 | % |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  |  |  |  |  |  |  |  | $ | - |  |  | $ | 64,689 |  |  | $ | (1,473 | ) |  | $ | (110 | ) |  | $ | 63,106 |
Summary of Investments in Associates | The following table presents current and non-current assets, current and non-current liabilities as well as revenues and profit or loss of the Company’s investments in associates:
|  | Current |  |  | Non-current |  |  | Current |  |  | Non-current |  |  |  |  |  |  |  |  |
Entity |  | assets |  |  | assets |  |  | liabilities |  |  | liabilities |  |  | Revenue |  |  | Loss 1 |
Agripharm |  | $ | 4,671 |  |  | $ | 90,716 |  |  | $ | 1,391 |  |  | $ | 10,896 |  |  | $ | - |  |  | $ | (557 | )
TerrAscend |  |  | 53,693 |  |  |  | 15,369 |  |  |  | 1,692 |  |  |  | - |  |  |  | - |  |  |  | (6,805 | )
Radicle |  |  | 2,576 |  |  |  | 4,382 |  |  |  | 94 |  |  |  | 7,174 |  |  |  | - |  |  |  | (506 | )
CHI |  |  | 12,160 |  |  |  | 123 |  |  |  | 364 |  |  |  | - |  |  |  | - |  |  |  | (3,949 | )
Bedrocan Brasil |  |  | 659 |  |  |  | - |  |  |  | 34 |  |  |  | - |  |  |  | - |  |  |  | (162 | )
Entourage |  |  | 1,749 |  |  |  | 224 |  |  |  | 2,056 |  |  |  | - |  |  |  | - |  |  |  | (2,061 | )
|  | $ | 75,508 |  |  | $ | 110,814 |  |  | $ | 5,631 |  |  | $ | 18,070 |  |  | $ | - |  |  | $ | (14,040 | )
1 For the year ended December 31 except for Agripharm which is from the period of December 1, 2017 to December 31, 2017 as this represents the period post derecognition

X
- Definition The disclosure of current and non-current assets and liabilities, and revenues for the Company's investment in associates. + References No definition available. + Details
Name: | cgc_SummaryOfFinancialStatementTotalsRelatingToAssociateInvestmentsExplanatory
Namespace Prefix: | cgc_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2017-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_10_e&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration